Evidence map›Paper›PMID 41388688›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Pseudotetraivprolides from Pseudomonas entomophila Provide Insights into the Biosynthesis of Detoxin/Rimosamide-Like Anti-Antibiotics.

Edna Bode, Julia Büllesbach, Kevin Bauer, Yan-Ni Shi, Simon Reiners, Ziheng Cui, Petra Happel, Yi-Ming Shi, Kevin Hoffmann, Peter Grün and 4 more

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Edna BodeDepartment of Natural Products in Organismic Interactions, Max Planck Institute for Terrestrial Microbiology, Marburg, 35043, Germany.ORCID 0000-0001-8522-1897
Julia Büllesbach *Molecular Biotechnology, Department of Biosciences, Goethe University Frankfurt, Frankfurt am Main, 60438, Germany.
Kevin Bauer *Institute for Organic Chemistry, Saarland University, Saarbrücken, 66123, Germany.
Yan-Ni Shi *Molecular Biotechnology, Department of Biosciences, Goethe University Frankfurt, Frankfurt am Main, 60438, Germany.
Simon Reiners *Buchmann Institute for Molecular Life Sciences, Institute of Organic Chemistry and Chemical Biology, Goethe University Frankfurt, Frankfurt am Main, 60438, Germany.
Ziheng Cui *Buchmann Institute for Molecular Life Sciences, Institute of Organic Chemistry and Chemical Biology, Goethe University Frankfurt, Frankfurt am Main, 60438, Germany.
Petra Happel *Department of Natural Products in Organismic Interactions, Max Planck Institute for Terrestrial Microbiology, Marburg, 35043, Germany.
Yi-Ming ShiDepartment of Natural Products in Organismic Interactions, Max Planck Institute for Terrestrial Microbiology, Marburg, 35043, Germany.
Kevin HoffmannDepartment of Natural Products in Organismic Interactions, Max Planck Institute for Terrestrial Microbiology, Marburg, 35043, Germany.
Peter GrünDepartment of Natural Products in Organismic Interactions, Max Planck Institute for Terrestrial Microbiology, Marburg, 35043, Germany.
Bianca PommerenkeDepartment of Biochemistry & Synthetic Metabolism, Max Planck Institute for Terrestrial Microbiology, Marburg, 35043, Germany.
Uli KazmaierInstitute for Organic Chemistry, Saarland University, Saarbrücken, 66123, Germany.
Martin GriningerBuchmann Institute for Molecular Life Sciences, Institute of Organic Chemistry and Chemical Biology, Goethe University Frankfurt, Frankfurt am Main, 60438, Germany.
Helge B BodeDepartment of Natural Products in Organismic Interactions, Max Planck Institute for Terrestrial Microbiology, Marburg, 35043, Germany.ORCID 0000-0001-6048-5909

Funding

ERC 835108
6 · The paper itself

Abstract

Novel variants of known natural product (NP) classes can provide valuable insights into their biosynthesis, mechanisms of action, and potential as drug leads across the entire class. Here, we describe a novel member of the widespread detoxine/rimosamide-like (DRL) natural products, named pseudotetraivprolide, produced by Pseudomonas strains. Pseudotetraivprolide exhibits the characteristic DRL-activity of protecting Bacillus cereus against the antibiotic blasticidin S. Through the generation of multiple deletion and complementation mutants, heterologous expression experiments, identification and structure elucidation of several derivatives, chemical synthesis of main derivatives, enzymatic characterization of individual biochemical steps, and detailed homology modelling of enzyme complexes, we elucidated key aspects of its biosynthesis. Our findings demonstrate that the primary metabolism-derived malonyl CoA:ACP transacylase (FabD) functions as a trans-AT in the biosynthesis pathway. Furthermore, we suggest an order for all late-stage modifications and assign a function for the three conserved hypothetical proteins PipDFG acting as last-step acetylation complex responsible for stabilization and activation of the final product.

Indexed as

Anti-Bacterial AgentsPseudomonasBacillus cereusBiological ProductsMolecular StructureAnti-Bacterial AgentsBiological ProductsAcetyl transferase protein complexNatural productNRPS/PKS hybrid biosynthesis pathwayThioesteraseTrans‐AT polyketide synthase

Identifiers

PMID41388688
PMCPMC12828459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.